文献速递妇科

复发性异常子宫出血中子宫内膜增生和子宫内膜癌的预测

Predicting Endometrial Hyperplasia and Endometrial Cancer on Recurrent Abnormal Uterine Bleeding.
PubMed 文献 · Obstet Gynecol · 2024-06-13

本回顾性队列研究纳入2013年1月至2021年12月间既往子宫内膜取样良性、后出现复发性异常子宫出血的456例患者,构建预测子宫内膜增生和子宫内膜癌的模型。子宫内膜增生和子宫内膜癌检出率分别为8.3%和2.2%,年龄大于45岁、未产、子宫内膜息肉史及取样间隔小于12个月为预测因素,模型AUC为73.1%。

要点

  • 复发性异常子宫出血患者中子宫内膜增生和子宫内膜癌的检出率分别为8.3%和2.2%。
  • 年龄大于45岁、未产、子宫内膜息肉史及取样间隔小于12个月为预测因素。
  • 风险评分分组0-3、5-8、9-11分对应的子宫内膜增生和子宫内膜癌风险分别为4.7%、15.5%、57.1%。

核心结论

  • 在复发性异常子宫出血患者中,子宫内膜增生和子宫内膜癌发生率较低,约占五分之一。
  • 年龄较大、未产、子宫内膜息肉史及取样间隔小于12个月是本队列中子宫内膜增生和子宫内膜癌的预测因素。

研究设计与样本

  • 回顾性队列研究,分析2013年1月至2021年12月间既往子宫内膜取样良性、后出现复发性异常子宫出血的患者。
  • 共纳入456例复发性异常子宫出血患者。
  • 采用多变量逻辑回归构建预测模型,根据各显著预测因素的对数比值比计算风险评分并分组。
  • 采用受试者工作特征曲线下面积(AUC)和bootstrap方法评估模型整体性能和内部验证。

主要发现

  • 456例复发性异常子宫出血患者中,子宫内膜增生检出率为8.3%,子宫内膜癌检出率为2.2%。
  • 首次与第二次子宫内膜取样之间的平均间隔为25.1个月。
  • 年龄大于45岁(比值比[OR] 2.86,95% CI 1.31-7.03)、未产(OR 3.50,95% CI 1.76-6.85)、子宫内膜息肉史(OR 3.69,95% CI 1.93-7.05)及取样间隔小于12个月(OR 2.36,95% CI 1.25-4.42)与子宫内膜增生和子宫内膜癌显著相关。
  • 风险评分分为0-3分、5-8分和9-11分三组,对应的子宫内膜增生和子宫内膜癌风险分别为4.7%、15.5%和57.1%。
  • 模型AUC为73.1%,平均绝对误差为0.01。

关键数值与推荐

  • 年龄大于45岁的OR为2.86(95% CI 1.31-7.03)。
  • 未产的OR为3.50(95% CI 1.76-6.85)。
  • 子宫内膜息肉史的OR为3.69(95% CI 1.93-7.05)。
  • 取样间隔小于12个月的OR为2.36(95% CI 1.25-4.42)。
  • 风险评分0-3分、5-8分、9-11分组的子宫内膜增生和子宫内膜癌风险分别为4.7%、15.5%、57.1%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To develop predictive models for endometrial hyperplasia and endometrial cancer in patients with recurrent abnormal uterine bleeding (AUB). METHODS: This retrospective cohort study analyzed patients with recurrent AUB who had previous endometrial sampling that showed benign results between January 2013 and December 2021. A model was constructed from the significant factors associated with endometrial hyperplasia and endometrial cancer using multivariate logistic regression. Risk scores were calculated from the log odds of each significant predictive factor and were subsequently subcategorized into risk groups. The overall performance and internal validation of the model were assessed with the area under the receiver operating characteristic curve (AUC) and bootstrap methods. RESULTS: Of the total 456 patients with recurrent AUB, endometrial hyperplasia and endometrial cancer were detected in 8.3% and 2.2% of cases, respectively. The average interval between the first and second endometrial samplings was 25.1 months. Factors significantly associated with endometrial hyperplasia and endometrial cancer included age older than 45 years (odds ratio [OR] 2.86, 95% CI, 1.31-7.03), nulliparity (OR 3.50, 95% CI, 1.76-6.85), a history of endometrial polyp (OR 3.69, 95% CI, 1.93-7.05), and an interval of less than 12 months between sampling (OR 2.36, 95% CI, 1.25-4.42). Predictive factors were scored and categorized into three groups: 0-3, 5-8, and 9-11 points. The corresponding risks for endometrial hyperplasia and endometrial cancer in these groups were 4.7%, 15.5%, and 57.1%, respectively. The AUC was 73.1%, with a mean absolute error of 0.01. CONCLUSION: Endometrial hyperplasia and endometrial cancer occur at low incidence among one-fifth of patients with AUB who experience recurrent bleeding. Older age, nulliparity, a history of endometrial polyps, and an interval of less than 12 months between samplings are predictive factors for endometrial hyperplasia and endometrial cancer in this cohort.

来源:Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Veeranaraphanit U, Saeaib N, Srisintorn W, et al. Predicting Endometrial Hyperplasia and Endometrial Cancer on Recurrent Abnormal Uterine Bleeding. Obstet Gynecol. 2024. PMID: 38870531. doi:10.1097/AOG.0000000000005641

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。